Positive SOF-SKN dosing data shows prolonged skin retention
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Noxopharm Ltd. has announced promising new preclinical data for its SOF-SKN drug candidate, which targets cutaneous lupus and shows prolonged skin retention of the active ingredient. The data supports the drug's sustained activity and indicates it remains primarily in the skin layers, minimizing systemic absorption.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Noxopharm
- Noxopharm appoints Dr Olivier Laczka as new CEO
- Resignation of Chief Executive Officer
- Appendix 4D and FY2026 Half Year Financial Report
- R&D rebate strengthens cash position
- At-the-Market (ATM) agreement with Acuity Capital
Later from Noxopharm
- March 2026 Quarterly Activities Report and Appendix 4C
- Innovative collaboration further expands Sofra platform
- New data shows SOF-SKN active ingredient efficacy
- Noxopharm progresses US regulatory strategy
- Noxopharms Sofra assets to be presented at global conference
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm